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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) integrase protein (IN), catalyzes the integration of viral DNA
into the host cell genome. IN catalyzes the first step of the integration process, namely the 39-end processing in which IN
removes a pGT dinucleotide from the 39 end of each viral long terminal repeat (LTR). Following nuclear import of the viral
preintegration complex, the host chromosomal DNA becomes accessible to the viral cDNA and the second step of the
integration process, namely the strand-transfer step takes place. This ordered sequence of events, centered on integration,
is mandatory for HIV replication.
Methodology/Principal Findings: Using an integrase peptide library, we selected two peptides, designated INr-1 and INr-2,
which interact with the Rev protein and probably mediate the Rev-integrase interaction. Using an in-vitro assay system, we
show that INr-1 and INr-2 are able to abrogate the inhibitory effects exerted by Rev and Rev-derived peptides on integrase
activity. Both INr-1 and INr-2 were found to be cell-permeable and nontoxic, allowing a study of their effect in HIV-1-infected
cultured cells. Interestingly, both INr peptides stimulated virus infectivity as estimated by production of the viral P24
protein, as well as by determination of the appearance of newly formed virus particles. Furthermore, kinetics studies
revealed that the cell-permeable INr peptides enhance the integration process, as was indeed confirmed by direct
determination of viral DNA integration by real-time PCR.
Conclusions/Significance: The results of the present study raise the possibility that in HIV-infected cells, the Rev protein
may be involved in the integration of proviral DNA by controlling/regulating the activity of the integrase. Release from such
inhibition leads to stimulation of IN activity and multiple viral DNA integration events.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) integrase
protein (IN), which is part of the Gag-Pol precursor, catalyzes the
integration of viral DNA into the host cell genome. It is contained in
the virion and following infection, it is released into the cytoplasm of
infected cells [1]. After a reverse-transcription step [2], IN becomes
part of the preintegration complex (PIC) which also includes the
newly obtained viral cDNA, as well as the viral matrix, Vpr, and
nucleocapsid proteins [1–8]. Within the cytoplasm, IN catalyzes the
first step of the integration process, namely the 39-end processing in
which an IN dimer removes a pGT dinucleotide from the 39 end of
each viral long terminal repeat (LTR) [9,10]. Following nuclear
import of the PIC, the host chromosomal DNA becomes accessible
to the viral cDNA and the second step of the integration process,
namely the strand-transfer step that is catalyzed by an IN tetramer,
takes place [9,11–13]. This ordered sequence of events, centered on
integration, is mandatory for HIV replication. Within the nuclei of
theinfectedcells,thecellularprotein,lensepithelium-derived growth
factor (LEDGF)/p75, as well as some other cellular cofactors assist
the integration process by tethering the IN to the host chromosomal
DNA [14,15].
Although each HIV-1 infected cell contains several copies of the
viral genome, only a limited number of integration events per cell,
mostly one or two, have been observed [16,17]. On the other
hand, in cells infected by other retroviruses such as murine
leukemia virus (MuLV) or Rous sarcoma virus (RSV), numerous
integration events per cell have been detected [18–21]. This
suggests that control of integration is different for HIV-1 thanfor
other retroviruses.
Recently, using bimolecular fluorescence complementation
(BiFC) and coimmunoprecipitation assay systems, we have shown
that the HIV-1 IN and Rev proteins can interact with each other
intracellularly [22].
Based on these results [22], we speculate that the limited
number of integration events observed in HIV-infected cells may
result from regulated inhibition of IN enzymatic activity by the
viral Rev protein.
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4155The karyophilic Rev protein, whose expression is promoted by
viral DNA, is required at the late phase of the viral replication cycle
for promoting nuclear export of partially spliced or un-spliced viral
RNA [23,24]. Rev nuclear export is crucial for Rev-dependent
activation of HIV gene expression [25]. In addition, Rev selectively
activates the production of structural HIV components, including
the HIV genome itself [24,26,27]. Interestingly, a few studies have
clearly indicated that several viral proteins—among them the Rev
protein—can be transcribed from nonintegrated viral DNA, the
amount ofwhich can reachupto 99% ofthe total viral DNApresent
in infected cells [28,29]. The Rev protein is thus also expressed at
early stages of virus infection, probably before the integration step
occurs [17,30–32]. The possibility that the Rev protein observed
before the integration step may arrive with the virus particles cannot
be eliminated. However the Rev protein was not, so far, reported to
be present in virus particles or in the PIC [1,3–7].
Following our previously described Rev-IN interaction [22], we
identified two short Rev-derived peptides’ derived from residues
13–23 and 53–67 of Rev, that inhibit IN enzymatic activities in
vitro and HIV-1 replication in cultured cells [22]. Similar to the
Rev-derived peptides also the Rev protein—as demonstrated in
the present work—is able to inhibit the enzymatic activity of IN.
In the present work we demonstrate that the Rev-mediated
inhibitory effect, as well as that exerted by the Rev 13–23 and Rev
53–67 peptides, can be abrogated by two selected IN-derived
peptides, designated INr-1 and INr-2, due to displacement of the
inhibitory molecules. Furthermore INr-1 and INr-2, which have
been found to be cell-permeable, stimulated integration of the
HIV-1 cDNA into host chromosomal DNA. Based on the results
obtained in the in-vitro assay systems, it is conceivable that the
effects seen in cells also resulted from dissociation of a putative IN-
Rev complex by these peptides. Thus, our present results further
support the view that intracellularly, the viral Rev protein may
inhibit/regulate IN activity.
Results
A) Selection of IN-derived peptides that interact with the
Rev protein and Rev-derived peptides
In order to further characterize the previously described Rev-IN
interaction [22], attempts were made, in the present work, to
identify the IN domains that mediate this interaction. Screening of
an IN peptide library (NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1
Consensus B Pol (15-mer) peptides – Complete Set from DAIDS,
NIAID) by an ELISA-based assay system (not shown) revealed that
two IN-derived peptides specifically interact with Rev-GFP
conjugates. These two peptides were designated as INr-1 and
INr-2 and their binding pattern and amino acids sequences are
shown Fig 1A and Table 1 respectively. The Rev protein itself was
Figure 1. INrs interact with Rev-GFP and Rev-derived peptides
in vitro and promote dissociation of Rev-IN complexes. (A) Rev-
GFP or GFP alone were incubated in ELISA plates coated with either INr-
1 (Green full and empty diamond respectively) or INr-2 (Magenta full
and empty square respectively) and binding was determined as
described in Materials and Methods. IN-Rev-GFP interaction was used
as positive control (Red triangle) (B) The IN protein was first bound to
the ELISA plate and then incubated with Rev-GFP to obtain a Rev-IN
complex. The complex was then incubated with either one or both of
the INr peptides at the designated Rev-GFP:peptide ratio. Wells were
then washed and the amount of bound Rev-GFP was determined by
mouse anti-GFP antibody and secondary rabbit anti-mouse HRP-
conjugated antibody. (C) Rev 13–23 and Rev 53–67 (conjugated to
biotinylated-BSA) were incubated in ELISA plates coated with either INr-
1 (Green empty and full diamond respectively) or INr-2 (Magenta full
and empty square respectively) and binding was estimated as described
in Materials and Methods. All other experimental conditions were as
described previously [37,55] and in Materials and Methods. (D)
Localization of INr-1 (green) and INr-2 (magenta) peptides within the
IN protein was determined using a protein model (PDB: 1EX4 [35]). A
clear model is shown on the left to illustrate the exact domains of INr-1
and INr-2 within the IN protein. Both models, left and right, emphasize
exposure of the INr sequences on the protein surface. The models
presented in this figure were generated using PyMOL v0.99 software
(DeLano Scientific LLC).
doi:10.1371/journal.pone.0004155.g001
Peptides Stimulate HIV DNA
PLoS ONE | www.plosone.org 2 January 2009 | Volume 4 | Issue 1 | e4155highly insoluble under our experimental conditions [33] and
therefore could not be used: instead, we used a Rev-GFP
conjugate that is soluble and functional [34]. Specific interaction
with the Rev protein was inferred from the results showing that
there is no such observable interaction with GFP alone. The
results in Fig 1B show that addition of INr-1 and INr-2 peptides to
the complex formed between IN and Rev-GFP induces the release
of the bound Rev-GFP. This observation further confirmed that
the sequences of the INr peptides within the IN protein mediate
the interaction with the Rev protein. INr-1 and INr-2 also
interacted with the Rev 53–67 and Rev 13–23 peptides,
respectively (Fig 1C and Table 1 and 2). This was inferred from
experiments showing that biotinylated-BSA-Rev 13–23 or Rev
53–67 conjugates were able to interact with INr peptides-coated
plates (Fig 1C). No binding was observed with biotinylated-BSA
alone (Fig 1C), indicating specific binding to the INr peptides. The
same specific interaction was observed when the order of addition
was reversed, namely, when soluble biotinylated-BSA-INr conju-
gates were incubated with plates coated with Rev 13–23 and Rev
53–67 (not shown). As is evident from the results in Fig 1C, INr-1
interacted with Rev 53–67 peptide but not with the Rev 13–23
peptide, while INr-2 interacted with Rev 13–23 but not with Rev
53–67, indicating specificity of interaction. Binding of the INrs to
the Rev-derived peptides showed somewhat higher affinity than to
the Rev protein itself, as indicated by their apparent Kds (Table 2).
Examination of the 3D structure of a truncated IN (aa52-288,
[35], PDB: 1EX4) revealed that the INr peptides are derived from
the surface-exposed region of the IN (Fig 1D).
B) Inhibition of the IN enzymatic activity by the Rev
protein and Rev-derived peptides: specific abrogation of
inhibition by the INr peptides
The results depicted in Fig 2A clearly show that the enzymatic
activity of IN is inhibited by Rev-GFP due to specific interaction
with the Rev protein itself and not with the GFP (Fig 2A). At a
Rev-GFP:IN (mole/mole) ratio of about 100, approx. 30%
inhibition was already observed, reaching up to 70% inhibition
at a ratio of 400 (Fig 2A). Interestingly, the INr peptides abrogated
the inhibitory activities of Rev-GFP (Fig 2B). The results in Fig 3A
confirm previously described results [22] showing that the Rev-
derived peptides (Rev 53–67 and Rev 13–23 blocked IN
Table 1. Interaction of IN peptides derived from an IN peptide library, with Rev-GFP or Rev-derived peptides.
NIH Cat # Amino acid residues within the IN Sequence* Peptide designated name Interacting with
5656 66–80 WTHLEGKIILVAVHVA INr-1 Rev 53–67, Rev-GFP
5669 118–128 WGSNFTSTTVKA INr-2 Rev 13–23, Rev-GFP
The ELISA binding system was used to screen for interactions between the IN peptide library and Rev-GFP protein as well as between the library and the two (inhibitory)
Rev-derived peptides (Fig 1).
*A tryptophan was added at the N’ terminus of the peptides in order to determine their concentrations.
For experimental details see Materials and Methods and Fig 1.
doi:10.1371/journal.pone.0004155.t001
Table 2. Quantitative characterization of the interaction
between the INrs and Rev-GFP or Rev-derived peptides.
Interaction between Apparent Kd [mM]
INr-1 : Rev-GFP 4166
INr-1 : Rev 53–67 - Bb 2361
INr-2 : Rev-GFP 2761
INr-2 : Rev 13–23 - Bb 1161
Apparent Kd of the interaction was obtained by the ELISA-based system and
their values were calculated as described in [64].
For experimental details see Materials and Methods and Fig 1.
doi:10.1371/journal.pone.0004155.t002
Figure 2. Inhibition of IN enzymatic activity by Rev and its
abrogation by the INr peptides. (A) Rev-GFP (dark green) or GFP
(turquoise) were incubated at different molar ratios with IN (390 nM)
and the IN enzymatic activity was determined as described previously
[22] and in Materials and Methods. (B) Rev-GFP was preincubated with
the indicated INr peptides at a molar ratio of 5:1 (peptide:Rev-GFP) and
the resultant mixture was added to a solution containing IN to give a
molar ratio of 1:200 and 1:400 (IN:Rev-GFP). Following an incubation
period, IN activity was estimated as described previously [22]. All other
experimental conditions are described in Materials and Methods.
doi:10.1371/journal.pone.0004155.g002
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(mol/mol) ratio of about 150 (Fig 3A and B). It is also evident that
the INr peptides were able to abrogate the inhibitory effect of the
Rev derived peptides on integrase activity. Integrase activity was
fully restored in the presence of both INr peptides at a molar ratio
of Rev:INr peptides of 1:5–1:10 (Fig 3A and B)). The fact that no
abrogation was observed when the Rev:INr peptides ratios was 1:1
can be explained by the affinity differences towards their binding
partners ([22] and table 2). This appeared to be due to the ability
of the INrs to specifically interact with Rev-GFP and the Rev-
derived peptides, since incubation with a scrambled peptide did
not restore the integrase activity (Fig. 3B).
As expected from their interaction specificity (see Table 1)
INr-1 abrogated the inhibitory effect of the Rev 53–67
peptide while INr-2 that exerted by the Rev 13–23 peptide
(fig 3A and B)
The INrs did not, by themselves, have any effect on IN enzymatic
activity (Fig 3E) or on Rev protein activity which was estimated by a
previously described method [25] (not shown). Further evidence for
the specific effect of the INrs in releasing the observed inhibition of
IN enzymatic activity can be inferred from the lack of effect of a
scrambled peptide (Fig 2B). As mentioned above and described
before in addition to the inhibitory Rev derived peptides we also
have identified two LEDGF peptides which blocked the IN
enzymatic activity [36]. However the INrs failed to abrogate the
inhibitory effect exerted on IN by LEDGF-derived inhibitory
peptides and Fig 3C and D), again emphasizing the specific
interaction between the INrs and the Rev protein and peptides.
Figure 3. Inhibition of IN activity by Rev- and LEDGF-derived peptides: specific abrogation by the INr peptides. IN (390 nM) was
incubated with 50 mM of the Rev-derived peptides (1:300 IN:Rev-derived peptide) [22] (Rev13–23 (A) and Rev 53–67 (B)) or LEDGF-derived peptides
[36] (LEDGF 361–370 (C)) and LEDGF 402–411 (D)) and then the INr peptides were added at different molar ratios ranging from 10:1 to 1:10 (Rev or
LEDGF peptide:INr peptide). (E) IN (390 nM) was incubated with the INr peptides (50 mM).
doi:10.1371/journal.pone.0004155.g003
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23 peptides in MAGI cultured cells: specific abrogation of
inhibition by INr peptides
It is evident from the results shown in Fig 4A that both INr-1
and INr-2 are cell-permeable peptides. Our results (Fig 4A)
showing that another peptide of about the same size, designated
IN-3 (see [37]), failed to penetrate the cultured HeLa cells clearly
indicate the integrity of the cells’ plasma membranes as well as
their viability (see also Fig 4B and C). No toxic effect was observed
when both peptides were incubated, up to about 62 mM, with
either HeLa TZM-bl cells (Fig 4B) or H9-T-cell lymphocytes
(Fig 4C). These results allowed us to study their effect on HIV-1
infection in cultured cells.
The results in Fig 5A-F and Table 3 show that the Rev-derived
peptides 13–23 and 53–67 were able to block HIV-1 infection in
cultured cells (see also ref [22]). This is in addition to their ability
to inhibit HIV-1 IN activity in vitro (see Fig 3). It was, therefore, of
interest to determine whether the cell-permeable nontoxic INr
peptides, similar to their effect in vitro, would be able to abrogate
the inhibitory effect of the Rev-derived peptides in cells.
As can be seen (Fig 5), the INrs were able to completely abrogate
the ability of the Rev peptides to inhibit HIV infection, regardless of
their order of addition. The same abrogation was obtained when the
INrs were added either before or after infection with HIV-1 or
incubationwith the Rev peptides(for details see legend toFig5).The
resultsshowingthatincubationwiththeRevpeptidesblockedHIV-1
infection bymorethan 85%(Fig5)strongly indicate the formation of
an intracellular nonactive IN-Rev peptide complex. This inhibition
was completely reversed by the addition of INr peptides (INr:Rev
molar ratio of 5:1) regardless of the order of addition (Fig 5). The
most interesting observation was that abrogation could be obtained
even when the INr peptides were added as the last component,
namely, after 4 h of incubation with HIV-1 and 2 h incubation with
the Rev peptides (Fig 5E). The same results were obtained following
4 h incubation with the Rev peptides and 2 h with HIV-1 (Fig 5C).
In both cases, abrogation can be explained by INr-induced
dissociation of the nonactive complex formed between the Rev
peptides and the IN protein. As expected (see also Fig 3), INr-1
blocked the inhibitory effect of Rev 53–67 but not of Rev 13–23,
while INr-2 had the same effect on Rev 13–23 but not on Rev 53–
67, again indicating specificity of interaction (Fig 5). Needless to say,
that the INr peptides did not have any effect by themselves on HIV
infection in MAGI HeLa cells (Fig 5). The results depicted in Fig 5
are summarized in Table 3.
D) INr peptides stimulate virus production and
integration of the HIV-1 genome in cultured cells
The results in Fig 6 show that preincubation of the INr peptides
with LC5-RIC cells prior to the addition of HIV-1 resulted in
significant stimulation of the infection efficiency, as estimated by
the expression of a fluorescence reporter gene [25,38,39]. Under
the experimental conditions used about seven fold stimulation has
been obtained with 33 mM of INr-1 following 120 hrs of infection
(Fig 6A). About the same stimulation of infection was observed by
7.5 mM of INr-2 but at 72–96 hrs post infection (Fig 6B). The
difference in the period required for obtaining maximal stimula-
tion between INr-1 and 2 may be due to a difference in the
stability and the activities (see Figs 2) of these two peptides. The
decrease in the stimulation degree observed at longer times with
INr-2 probably results from an increase in cell death and syncytia
formation induced by the combination of the peptide and the virus
(not shown). Stimulation of infection by the INr peptides was also
observed when it was assayed by the appearance of the viral p24
antigen in H9 and Sup-T1 cultured cells (Fig 7A and B). The same
stimulation was also observed when the efficiency of infection was
determined by the appearance of infectious viral particles (Fig 7C
and D). Stimulation of the infection was slightly enhanced when a
mixture of INr-1 and INr-2 was incubated with the cells (Fig 7).
The results depicted in Fig 8 clearly indicate that the observed
stimulation by the INrs is not due to increases in either virus
adsorption or reverse-transcriptase activity. Fig 8A and B demon-
strate that the reverse transcription step was not effected by the
addition of the INr peptides. This view is further supported by the
kinetics studies described inFig 8C.Dextran sulfate, variouspeptides
and AZT were added at different times to HIV-1 infected Sup-T1
cells and the amount of viral P24 protein—reflecting efficiency of
virus infection—was estimated at 48 h PI. As expected, dextran
sulfate—which inhibits virus absorption [40–42]—blocked virus
infection only when added during the first 4 h PI. AZT—which
inhibits the viral reverse transcriptase [43]—blocked infection when
added within the first 10 h of infection (Fig 8C). To reveal the time
period during which the integration process occurs, LEDGF-derived
Figure 4. Cell penetration and toxicity of INr peptides. (A)
Fluorescein-labeled INr-1, INr-2, and IN-3 (a known nonpermeable
peptide [37]) each at 10 mM, were incubated for 2 h at 37uC with HeLa
cells. The cells were then washed three times with PBS and visualized by
confocal microscopy. (B) Cell toxicity was determined by MTT assay in
HeLa TZM-bl cells. (C) Same as (B) but in H9 lymphocytes. Experimental
conditions are described in Materials and Methods.
doi:10.1371/journal.pone.0004155.g004
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enzymatic activity in vitro and in vivo [36] was used as a marker. It is
clearthatthe LEDGF-derived peptide exertedits inhibitoryeffect up
to about 18 h PI. During this time, the INr peptides showed a clear
stimulatory effect which terminated shortly after the ‘‘integration
period’’ (between 6 and 18 h PI).
INr stimulation of the integration process was also observed
when insertion of the viral DNA into the host DNA was estimated
directly. As can be seen (Fig 9A and B), a ca. 2- to 2.5-fold
stimulation of integration per cell was obtained following a single
cycle of viral infection, while between 5- and 10-fold stimulation of
integration was observed 8 days PI. Again, in both cases,
integration stimulation was slightly enhanced when a mixture of
the INr peptides was added to the cells.
Discussion
It has been well established that following reverse transcription
of the retroviral genome, the transcribed cDNA is integrated into
the host chromosomal DNA, a process which is catalyzed by the
Figure 5. Inhibition of HIV-1 infection by the Rev-derived peptides and abrogation of inhibition by INrs. HeLa MAGI TZM-bl cells were
incubated with Rev-derived (12.5 mM of Rev 13–23 or Rev 53–67) and INr (62.5 mM of INr-1 or INr-2) peptides and infected with HIV-1 Delta-env/VSV-
G. at different orders of addition as indicated by arrows, A) Rev peptide.INr.HIV-1; (B) INr.Rev peptide.HIV-1; (C) Rev peptide.HIV-1.INr; (D)
INr.HIV-1.Rev peptide; (E) HIV-1.Rev peptide.INr; (F) HIV-1.INr.Rev peptide. Control cells were incubated with none or only one of the
indicated peptides. The length of the incubation period with each of the above-described components (HIV-1, Rev and INr peptides) was 2 h at 37uC
and at the end of the total 6-h incubation, the infected cells were left for a further 48-h incubation. At the end of the incubation period, the number
of blue cells per well was estimated as described in Materials and Methods. (A summary of the results is presented in Table 3).
doi:10.1371/journal.pone.0004155.g005
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chromosomal DNA vary among different members of the
Retrovirus family [44]. Integration of the HIV genome appears
to favor active genes, while that of MuLV shows a strong bias for
the transcription start sites and that of Avian sarcoma-leukosis
virus (ASLV) does not exhibit any preference in its random
integration into the host genome [44]. The number of integration
events per cell also varies between different members of the
retroviruses. Quantitative estimation has revealed that in cells
infected by MuLV, there are 9 to14 detectable proviruses per
individual host genome [18,19], while in cells transformed by
RSV, four to six integration events per haploid genome have been
observed [20]. As many as 30 integration events per genome have
been estimated in cells transformed by the Salmon swim bladder
sarcomas retrovirus (SSSV) [45]. In contrast, in the case of HIV-1,
which belongs to the lentiviruses (a subgroup of the Retrovirus
family) [46], the number of integration events per genome is much
more limited, apparently not exceeding two integration events per
cell [16]. Since in practice, a relatively high number of lentiviral
genome copies are available for integration, this low number of
integration events is unexpected [16,28,29]. It has been reported
that more than 20 reversed-transcribed cDNA molecules are
present in each infected cell, most of which remain unintegrated
[16,28,29]. Thus it appears that the large majority of the viral
cDNA is prevented from integration. It may thus be speculated
that while the IN of HIV-1 is subjected to a controlled-inhibition
process, that of viruses such as MuLV or RSV is not.
Our present results clearly show that IN-derived peptides, which
by themselves have no effect on IN enzymatic activity in vitro, greatly
stimulate the integration of viral DNA in HIV-1 infected cells. Using
an in-vitro integration assay system, we show that these peptides,
namely INr-1 and INr-2, abrogate inhibition of integrase activity by
the Rev protein as well as by the Rev-derived peptides. On the other
hand, the INr peptides failed to abrogate the inhibitory effects of two
LEDGF derived peptides [36], strengthening the view that the
abrogation is due to specific interactions of the INr peptides with the
Rev protein or Rev derived peptides. Specificity of interaction is
further emphasized by our results showing that while the two INr
peptides abrogated the inhibitory effect of Rev, INr-1 was able to
abolish only the inhibitory effect of Rev 53–67, while INr-2 only that
of Rev 13–23. Being cell permeable, the two INr peptides were able
to abrogate the inhibitory effect exerted by the Rev peptides on the
degree of virus infection. Furthermore both INr peptides enhanced
virus infection in three different assay systems. Thus, the
combination of the in-vitro and in-vivo (in cultured cells) experiments
raise the interesting possibility that the limited number of integration
events per cell may result from the interaction between the viral IN
and the Rev protein, resulting in inhibition of HIV-1 IN activity.
The INr peptides – as shown here – promote the dissociation of the
IN-Revcomplexes,thusallowingINto befullyactive andenhancing
the integration process.Our results clearly showthatincubation with
the INr peptides stimulate viral DNA integration leading to multiple
integration events. Thus these data further support the view that
intracellularly, the viral Rev protein may inhibit/regulate IN activity
and release from such inhibition may leads to stimulation of IN
activity and multiple viral DNA integration events.
Recent results obtained in our laboratory, using various virus
strains and different cell lines strongly support the suggested
regulatory mechanism namely inhibition of viral DNA integration
by the viral Rev protein (not shown and will be published elsewhere).
It is our view that the cell death and syncytia formation
observed following infection of INr treated cells results from
numerous integration events observed in these cells. The fact that
a Rev analogue protein is absent from retroviruses, in which a high
number of integration events per cell has been observed, further
supports our present assumption that the viral Rev protein
controls/regulates the integration process in HIV-1 infected cells.
Experiments are underway in our laboratory to better
characterize the regulation of IN activity, especially by following
the IN-Rev interaction in virus-infected cells.
Materials and Methods
Protein expression and purification
Expression and purification of histidine-tagged Rev-GFP were
performed as described previously [34]. The histidine-tagged IN
expression vector was a generous gift from Dr. A. Engelman
(Department of Cancer Immunology and AIDS, Dana-Farber
Table 3. Inhibition of HIV-1 infection by the Rev-derived peptides and its abrogation by the INr peptides are not affected by order
of addition: a summary of the results described in Figure 5.
Peptides Rev peptide INr Rev peptide INr Infection Infection
Q QQ QQQ
INr Rev peptide Infection Infection Rev peptide INr
Q QQ QQQ
Infection Infection INr Rev peptide INr Rev peptide
Rev 13–23+INr-1 13611 2 611 3 611 3 621 5 611 6 61
Rev 13–23+INr-2 110651 2 1 62 10563 118621 1 9 651 2 3 62
Rev 53–67+INr-1 113631 2 1 61 11062 120641 1 9 631 2 3 64
Rev 53–67+INr-2 15611 4 611 4 621 5 611 7 611 6 62
Rev 13–23 12611 2 611 2 611 2 611 2 611 2 61
Rev 53–67 14621 4 621 4 621 4 621 4 621 4 62
INr-1 122631 2 2 63 12263 122631 2 2 631 2 2 63
INr-2 121631 2 1 63 12163 121631 2 1 631 2 1 63
No peptide 121631 2 1 63 12163 121631 2 1 631 2 1 63
The numbers presented are blue Magi TZM-bl cells/well.
doi:10.1371/journal.pone.0004155.t003
Peptides Stimulate HIV DNA
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Boston, Massachusetts, United States of America) and its
expression and purification were performed essentially as de-
scribed in Jenkins et al. [47].
Mammalian cultured cells
Monolayer adherent HeLa, HEK293T, LC5-RIC and HeLa
MAGI cells (TZM-bl) [48] expressing the b-galactosidase gene
under regulation of the transactivation response element [49] were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM). The T-
lymphocyte cell lines Sup-T1 and H9 were grown in RPMI 1640
medium. Cells beside the LC5-RIC cells were provided by the
NIH Reagent Program, Division of AIDS, NIAID, NIH, USA and
were incubated at 37uC in a 5% CO2 atmosphere. All media were
supplemented with 10% (v/v) fetal calf serum, 0.3 g/l L-
glutamine, 100 U/ml penicillin and 100 U/ml streptomycin
(Biological Industries, Beit Haemek, Israel).
Peptide synthesis, labeling and purification
Peptides were synthesized on an Applied Biosystems (ABI) 433A
peptide synthesizer. For cellular-uptake studies, the peptides were
labeled with fluorescein at their N terminus [50]. The peptides were
also labeled with Trp at their N terminus for UV spectroscopy.
Peptide purification was performed on a Gilson HPLC using a
reverse-phase C8 semi-preparative column (ACE, advanced chro-
matography technologies, USA) with a gradient from 5% to 60%
Figure6.INrpeptidesstimulateHIV-infectionofLC5-RICcultures.LC5-RICreportercellscontainanintegratedreportergenefor HIV-dependent
productionofaredfluorescentprotein.LC5-RICcultureswereincubatedwithHIV-1IIIBandpeptideINr-1(A)orINr-2(B)attheindicatedconcentrations
andthefluorescent intensitiesofthe culturesmeasuredaftertheindicatedtimeperiods.Thegraphshowsthe overallfluorescentintensitiesmeasuredin
peptide-containing cultures relative to HIV-exposed cultures incubated without peptide (solvent only) for the same time period.
doi:10.1371/journal.pone.0004155.g006
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acid). Peptide concentrations were determined using a UV spectro-
photometer (Shimadzu Kyoto, Japan)as described previously [51].
Viruses
Wild-type HIV-1 was generated by transfection [52] of
HEK293T cells with pSVC21 plasmid containing the full-length
HIV-1HXB2 viral DNA [53]. Wild-type and Denv/VSV-G [54]
viruses were harvested from HEK293T cells 48 and 72 h post-
transfection with pSVC21 Denv. The viruses were stored at 275uC.
ELISA-based binding assays
Protein-peptide binding was estimated using an ELISA-based
binding assay exactly as described previously [55]. Briefly,
Maxisorp plates (Nunc) were incubated at room temperature for
2 h with 200 mlo f1 0mg/ml synthetic peptide in carbonate buffer.
After incubation, the solution was removed, the plates were
washed three times with PBS, and 200 ml of 10% BSA (Sigma) in
PBS (w/v) was added for 2 h at room temperature. After
rewashing with PBS, Rev-GFP, GFP alone or biotinylated-BSA-
peptide conjugates (dissolved in PBS containing 10% BSA to give
the appropriate concentrations (see legends to figures)), were
added for further incubation for 1 h at room temperature.
Following three washes with PBS, the concentration of bound
biotinylated molecules was estimated after the addition of
streptavidin-horseradish peroxidase (HRP) conjugate (Sigma), as
described previously [56]. The concentration of bound protein
molecules was estimated after the addition of anti-GFP mouse
antibody (Santa Cruz) which then was interacted with rabbit anti-
mouse IgG antibody conjugated to HRP. The enzymatic activity
of HRP was estimated by monitoring the product’s optical density
(OD) at 490 nm using an ELISA plate reader (Tecan Sunrise).
Each measurement was performed in duplicate.
Determination of integrase activity
The IN enzymatic activity assay was performed using a previously
described assay system [57,58]. Briefly, the oligonucleotide substrate
consisted of one oligo (59-ACTGCTAGAGATTTTCCACACT-
GACTAAAAGGGTC-39) labeled with biotin at the 39 end and the
other oligo (59- GACCCTTTTAGTCAGTGTGGAAAATCTC-
TAGCAGT-39) labeled with digoxigenin at the 59 end. When
inhibition was studied, the IN was preincubated with the peptide or
protein for 15 min prior to addition of the DNA substrate. The
entire IN reaction was followed by immunosorbent assay on avidin-
coated plates as described previously [22,58].
Cell-penetration experiments
Fluorescein-labeled peptides at a final concentration of 10 mM
in PBS were incubated with HeLa cells for 1 h at 37uC. After three
washes in PBS, cells were visualized by a confocal microscopy as
described previously [22].
Effect of peptides on cell viability using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay
Following incubation of the cells with the indicated peptides, the
medium was removed and the cells were further incubated in
Figure 7. Stimulation of HIV-1 replication by the INrs. The INrs (12.5 mM) were incubated with H9 cells (A and C) and Sup-T1 lymphocyte cells
(B and D) which were then infected with HIV-1 (MOI 0.01) as described in Materials and Methods. The amount of viral P24 (A and B) and virus titer
(C and D) were determined every 2 days by ELISA and MAGI assay [49], respectively. All other experimental conditions are described in Materials and
Methods. The concentration of AZT used was 2 mM.
doi:10.1371/journal.pone.0004155.g007
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the solution was removed and the cells were dissolved in 100 ml
DMSO for 10 min at room temperature. The DMSO-solubilized
cells were transferred to a 96-well ELISA plate and OD values
were monitored at a wavelength of 570 nm.
HIV-1 titration by Multinuclear Activation of a
Galactosidase Indicator (MAGI) assay
Quantitative titration of HIV-1 was carried out using the MAGI
assay, as described by Kimpton and Emerman [49]. Briefly, TZM-
b1 cells were grown in 96-well plates at 1610
4 cells per well and
following 12 h incubation at 37uC, peptides were added; after an
additional 2 h of incubation, the cells were infected with 50 mlo f
serially diluted virus (HIV-1 Denv/VSV-G or wild-type HIV-1
which was obtained from infected lymphocytes every 2 days) as
described [49]. Two days post-infection (PI), cultured cells were
fixed and b-galactosidase was estimated exactly as described
previously [49]. Blue cells were counted under a light microscope
at 2006magnification.
Infection of cultured lymphocyte cells with HIV-1
Cultured lymphocytes (1610
5) were centrifuged for 5 min at
2000 rpm and after removal of the supernatant, the cells were
resuspended in 0.2 to 0.5 ml of RPMI 1640 medium containing
virus at a multiplicity of infection (MOI) of 0.01 and 5. Following
absorption for 2 h at 37uC, the cells were washed to remove
unbound virus and then incubated at the same temperature for an
additional 1 to 8 days [22].
Quantitative estimation of HIV-1 infection by
determination of extracellular p24
Lymphoid cells were incubated with the indicated peptides for
2 h and following infection with wild-type HIV-1 at a MOI of 0.01
(as described above), the cells were incubated for 8 days, or 48 h at
a MOI of 1. The amount of p24 protein was estimated in the cell
medium every 2 days exactly as described previously [22].
PCR analysis of early viral genes
Sup-T1 cells were incubated with 12.5 mMo fp e p t i d e so rw i t h
2 mM azidothymidine (AZT) for 2 h and then were infected with
HIV-1 Denv/VSV-G virus at a MOI of 2, and further incubated for
6 h . The viral Gag or Nef DNA sequences were amplified using
specific primers: Gag-specific primers, 59-AGTGGGGGGACAT-
CAAGCAGCCATG-39 and 59-TGCTATGTCAGTTCCCCTT-
Figure 8. Virus-cell adsorption and viral reverse-transcriptase
activity are not affected by the INr peptides. (A and B)
Estimation of viral DNA in virus-infected cells: Sup-T1 cells were
incubated with the indicated peptides or with AZT for 2 h and then
were infected with HIV. Following another 6 h incubation, the viral Gag
(A) or Nef (B) DNA sequences were amplified using specific primers.
The reaction was terminated after 30 cycles. Lanes: 1) INr-1 (12.5 mM); 2)
INr-2 (12.5 mM); 3) AZT (2 mM); 4) untreated cells; 5) uninfected cells.
Note that in the AZT-treated cells, reverse-transcribed viral DNA is
absent. (C) Influence of the time of addition on P24 production [59]:
Sup-T1 cells were infected with HIV-1 at a MOI of 2, and the indicated
constituents were added at different time points PI (0, 2, 4,…, 24 h).
Viral p24 was determined at 48 h PI. No addition (Blue X); no virus (Gray
diamond); dextran sulfate 20 mM (Brown asterisk); AZT 2 mM (Red
empty circle); INr-1 12.5 mM (Green diamond); INr-2 12.5 mM (Magenta
square); LEDGF 402–411 (Black full circle). All other experimental
conditions are described in Materials and Methods.
doi:10.1371/journal.pone.0004155.g008
Figure 9. Stimulation of viral DNA integration events by the INr
peptides. H9 T-lymphoid cells were incubated with the indicated
peptides (12.5 mM) or AZT (2 mM) and following HIV-1 infection, the
integrated viral DNA/cell was assessed by real-time PCR following: (A) a
single cycle of infection at a MOI of 5 of Delta-env/VSV-G HIV-1 or (B) 8
days PI at a MOI of 0.01 of wild-type HIV-1. All other experimental
conditions are described in Materials and Methods and in Ref. [22].
doi:10.1371/journal.pone.0004155.g009
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CACAAGAG-39 and 59-CTTGTAGCAAGCTCGATGTC-39.
The fragments were amplified from 10 ng of total cell DNA in a
25-ml reaction mixture containing 16PCR buffer, 3.5 mM MgCl2,
200 mM dNTPs, 300 nM primers, and 0.025 units/mlo fTaq
polymerase. The PCR conditions were as follows: a DNA
denaturation and polymerase activation step of 5 min at 95uCa n d
then 29 cycles of amplification (95uC for 45 s, 60uC for 30 s, 72uC
for 45 s).
Time-of-addition assay (the time at which various
components were added on virus infected cultured cells)
Sup T1 cells were infected with wild-type HIV-1 at a MOI of 2,
and the test compounds were added at different time points after
infection (0, 2, 4,…, 24 h). Viral p24 production was determined
at 48 h PI [59]. Dextran sulfate was tested at 20 mM, AZT at
2 mM, LEDGF 402-411, INr-1 and INr-2 at 12.5 mM.
Quantitative analysis of the copy numbers of HIV-1 DNA
integrated into cellular genome
The integration reaction was estimated essentially as described
previously [22]. Briefly, following incubation of the indicated peptides
with H9 or Sup-T1 cells for 2 h, the cells were infected with a HIV-1
Denv/VSV-G virus at a MOI of 5 (as described above) for 24 h or
with wild-type HIV-1 at a MOI of 0.01 for 8 days. Integrated HIV-1
sequences were amplified by two PCR replication steps using the
HIV-1 LTR-specific primer (LTR-TAG-F 59-ATGCCACGTAA-
GCGAAACTCTGGCTAACTAGGGAACCCACTG-39)a n dA l u -
targeting primers (first-Alu-F 59-AGCCTCCCGAGTAGCTG-
GGA-39 and first-Alu-R 59-TTACAGGCATGAGCCACCG-39)
[60]. Alu-LTR fragments were amplified from 10 ng of total cell
DNA in a25-mlreactionmixture containing16PCRbuffer,3.5 mM
MgCl2,2 0 0mM dNTPs, 300 nM primers, and 0.025 units/mlo fTaq
polymerase. The first-round PCR cycle conditions were as follows: a
DNA denaturation and polymerase activation step of 10 min at 95uC
and then 12 cycles of amplification (95uCf o r1 5s ,6 0 uC for 30 s,
72uCf o r5m i n ) .
During the second-round PCR, the first-round PCR product
could be specificallyamplifiedbyusingthetag-specificprimer (tag-F
59-ATGCCACGTAAGCGAAACTC-39) and the LTR primer
(LTR-R 59-AGGCAAGCTTTATTGAGGCTTAAG-39) de-
signed by PrimerExpress (Applied Biosystems) using default settings.
The second-round PCRwasperformed on 1/25thof the first-round
PCR product in a mixture containing 300 nM of each primer,
12.5 mlo f2 6SYBR Green master mixture (Applied Biosystems) at
a final volume of 25 ml, run on an ABI PRIZM 7700 (Applied
Biosystems). The second-round PCR cycles began with DNA
denaturation and a polymerase-activation step (95uC for 10 min),
followed by 40 cycles of amplification (95uC for 15 s, 60uC for 60 s).
For generation of a standard calibration curve, the SVC21
plasmid containing the full-length HIV-1HXB2 viral DNA was used
as a template. In the first-round PCR, the LTR-TAG-F and LTR-
R primers were used and the second-round PCR was performed
using the tag-F and LTR-R primers. The standard linear curve
was in the range of 5 ng to 0.25 fg (R=0.99). DNA samples were
assayed with quadruplets of each sample. For further experimental
details see ref [22]. The cell equivalents in the sample DNA were
calculated based on amplification of the 18S gene by real-time
PCR as described in [61].
Determination of HIV-1 infection by the LC5-RIC assay
LC5-RIC cells is a HeLa-derived cell line that contains a
retroviral vector encoding the human CD4 gene [62] and the Rev-
inducible reporter construct pLRed2xINSR, (described in
[25,38,39]).
Cells were kept under standard cell culture conditions using
Dulbecco’s Modified Eagle Medium with 10% fetal calf serum
(FCS) and 2 mM Glutamax I (Invitrogen, Karlsruhe, Germany).
For primary infection assays, LC5-RIC cells were seeded at a
density of 1.4610
4 cells per well in 96-well plates (Falcon). Peptide
stock solutions were prepared by dissolving peptides in 80%
DMSO, 20% H2O. Twenty four hours later, serial dilutions of
peptide stock solutions prepared in fresh cell culture medium were
added to each well. Final peptide concentrations in each well are
indicated in Fig 6. In addition, wells were treated with serial
dilutions of the solvent lacking the peptide to control for solvent
effects. After 30 minutes pre-incubation, supernatant from the
HIV-1 producer cell line KE37/1-IIIB [63] containing 5610
7
RNA copies of HIV-1 was added to each well. Three wells were
incubated with supernatant from uninfected KE37/1 cells as
negative controls. Cells were incubated for the time periods
indicated in Fig 6 at 37uC, washed twice with PBS and red
reporter fluorescence was estimated in a microplate fluorimeter
(ThermoFisher).
All the results described in the present study are averages of at
least three–four determinations, where the standard deviation
never exceeded 620%.
Error bars were calculated using standard deviation function of
Microsoft Excel
TM.
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